Related to Positive Phase III Data Mean Cosmo and Santarus Plan 2011 NDA for Ulcerative Colitis Drug

• AstraZeneca Pulls the Plug on Asthma Collaboration with MAP Pharmaceuticals
  
• BioXell Welcomes Cosmo’s Proposed $40.9M Acquisition
  
• Santarus Licenses Approved Antidiabetic from S2 Therapeutics and VeroScience
  
• Pharming Earns $15M Up Front as Part of Deal with Santarus for HAE Drug
  
• Prometheus and UCLA to Validate IBD Mucosal Healing Markers
  
• FDA Refuses to File Pharming's BLA for EU-Approved HAE Therapy
  
• BioLineRx Licenses Phase II-Ready IBD Drug from Hebrew University
  
• Santarus and Depomed Amend U.S. Commercialization Arrangement for Type 2 Diabetes Drug
  
• Investigators Identify CD8 T Cell Transcription Signature that Predicts Prognosis in Crohn's and Ulcerative Colitis
  
• Tolerogenic Functions of Epidermal Langerhans Cells Point at Future Treatments for Inflammatory Bowel Disease
  
• Avaxia Raises $2.2M to Take Oral Antibody IBD Candidate into Clinical Trials
  
• Synthetic Molecules Trigger MMP-Targeting mAbs to Treat IBD
  
• Akebia Spins out Aerpio to Develop Tie-2 Activators and HIF-1a Stabilizers
  
• Dr. Falk Licenses European Rights to Lipid’s Ulcerative Colitis Therapy
  
• Enterome Raises €5M to Develop Gut Bacteria-Based Disease and Drug-Response Biomarkers
  
• Travelers’ Diarrhea Drug Success in First Phase III Study
  
• Common Forms of IBD Overlap Genetically
  
• Galapagos Granted Additional €2.5M from IWT
  
• Centocor’s Remicade Achieves Phase III Success Against Pediatric Ulcerative Colitis
  
• Positive Phase III Data Leads Cosmo to Project U.S. and EU Filing for UC Drug in 2011